Daxor Corporation (DXR)
7.23
-0.02 (-0.28%)
At close: Feb 20, 2025, 3:38 PM
7.23
0.00%
After-hours: Feb 20, 2025, 03:38 PM EST
undefined% (undefined)
| Bid | 7 |
| Market Cap | 34.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.16 |
| PE Ratio (ttm) | 6.23 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 8.72 |
| Volume | 5,667 |
| Avg. Volume (20D) | 12,606 |
| Open | 7.25 |
| Previous Close | 7.25 |
| Day's Range | 7.14 - 7.49 |
| 52-Week Range | 6.55 - 10.00 |
| Beta | undefined |
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Jul 25, 1983
Employees 37
Stock Exchange NASDAQ
Ticker Symbol DXR
Website https://www.daxor.com
Analyst Forecast
According to 1 analyst ratings, the average rating for DXR stock is "Strong Buy." The 12-month stock price forecast is $24.75, which is an increase of 242.32% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
